Core Viewpoint - The company has received formal acceptance for its clinical trial application for the new veterinary drug, Isu-Paglutide α, aimed at treating diabetes in pets, which is expected to begin Phase I clinical trials in the first quarter of 2026 [1] Group 1: Product Development - The company’s core product, Isu-Paglutide α, is intended for the treatment of diabetes in pets [1] - The company has successfully completed all preclinical trials and met the regulatory standards set by the Ministry of Agriculture and Rural Affairs [1] - Positive results regarding efficacy and safety from preclinical trials provide a reasonable basis for subsequent clinical trials and registration applications [1] Group 2: Market Potential - The board believes that developing diabetes medications for pets has significant market potential due to increasing consumer willingness to spend on extending the lifespan of pets [1] - This research aligns with the company's long-term business development strategy and will lay a solid foundation for entering the pet pharmaceuticals market [1]
银诺医药-B：依苏帕格鲁肽α的新兽药临床试验申请获受理